1/14
08:42 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/11
01:03 am
capr
Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at
Wall S
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at
Wall S
1/10
04:37 am
capr
Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]
Low
Report
Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]
1/9
06:31 am
capr
Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]
Medium
Report
Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]
1/3
01:06 am
capr
Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at
Wall Str
High
Report
Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at
Wall Str
12/18
01:32 pm
capr
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
Low
Report
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
12/16
04:05 pm
capr
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Low
Report
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
12/15
10:04 am
capr
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.
12/15
09:03 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
12/10
03:37 pm
capr
Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]
Low
Report
Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]
12/10
07:21 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/8
08:13 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/6
05:27 am
capr
How Recent Developments Are Rewriting the Story for Capricor Therapeutics [Yahoo! Finance]
Medium
Report
How Recent Developments Are Rewriting the Story for Capricor Therapeutics [Yahoo! Finance]
12/6
01:21 am
capr
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript [Seeking Alpha]
Medium
Report
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript [Seeking Alpha]
12/5
07:55 am
capr
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock [Yahoo! Finance]
12/5
06:35 am
capr
Capricor Therapeutics prices $150M stock offering [Seeking Alpha]
Low
Report
Capricor Therapeutics prices $150M stock offering [Seeking Alpha]
12/5
06:15 am
capr
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Medium
Report
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
12/4
04:57 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
12/4
04:01 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
12/4
12:01 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.
11/24
09:00 am
capr
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
High
Report
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
11/11
06:02 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
11/11
12:30 am
capr
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
11/10
11:24 pm
capr
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
Medium
Report
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
11/10
04:04 pm
capr
Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 [Seeking Alpha]
Medium
Report
Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 [Seeking Alpha]